FAKTOR ZERTIFIKAT LONG - ASTRAZENECA | Market Closed - Borsa Italiana 21:04:59 24/05/2024 BST | ||
| 38.4 EUR | -0.83% |
|
| Current month | +10.20% | ||
| 1 month | +41.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/05/24 | 38.37 | -0.90% |
| 23/05/24 | 38.72 | +5.79% |
| 22/05/24 | 36.6 | -9.34% |
| 21/05/24 | 40.37 | +15.67% |
| 20/05/24 | 34.9 | -2.02% |
Real-time Borsa Italiana
Last update May 24, 2024 at 09:04 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| SAZNL5 | |
| ISIN | DE000SW8FX82 |
| Date issued | 08/04/2024 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.75 € |
|---|---|
| Lowest since issue | 19.05 € |
| Spread | 1.1 € |
| Spread % | 2.82% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
156.7
USD
Average target price
170.1
USD
Spread / Average Target
+8.53%
- Stock Market
- Certificates
- SAZNL5 Certificat
